Urinary tract infection in chronic kidney disease patients
PDF (Español (España))
HTML (Español (España))


urinary tract infections, chronic kidney disease, renal replacement therapy, dialysis, kidney transplantation, hospitalization.

How to Cite

García- Agudo R, Panizo N, Proy Vega B, García Martos P, Fernández Rodríguez A. Urinary tract infection in chronic kidney disease patients. Rev. Colomb. Nefrol. [Internet]. 2020 Jan. 7 [cited 2021 Dec. 7];7(1). Available from: https://www.revistanefrologia.org/index.php/rcn/article/view/264


Infections in chronic kidney disease patients are a major cause of morbidity and mortality. Renal patients have specific risk factors for acquiring infections, which also tend to be more severe and have a more rapid progression and slower resolution than in the healthy individuals. Urinary tract infection in renal patients is often complicated due to the presence of diabetes, multiresistant microorganisms, anatomic or functional abnormalities of the urinary tract, metabolic disturbances and the frequent use of urinary catheters. It causes one of the highest rates of hospitalization among dialysis patients and is highly prevalent in kidney transplantation. The aim of this work is to review the etiology, microbiological diagnosis and treatment of urinary tract infections in chronic kidney disease patients.

PDF (Español (España))
HTML (Español (España))


Ll. A. Localización de las infecciones. Prevalencia de las infec- ciones en los hospitales españoles. Estudio EPINE. Resultados de los estudios de 2004, 2005, 2006 y 2007 y evolución 1990-2007: 18 años. Medicina Preventiva 2008;14:22-6.

KDIGO. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international 2012;(Suppl) 2013(3 (1)):1-308.

Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney international 2000;58(4):1758-64. Available from: https://doi.org/10.1111/j.1523-1755.2000. 00337.x

Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006;13(3):199-204. Available from: https://doi.org/ 0.1053/j.ackd.2006.04.004

Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356-63. Available from: https://doi.org/10.1053/j.ajkd.2011.07.012

James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, et al. CKD and risk of hospitalization and death with pneumonia. American journal of kidney diseases: the official journal of the National Kidney Foundation 2009;54(1):24-32. Available from: https://doi.org/10.1053/j.ajkd.2009.04.005

McDonald HI, Thomas SL, Nitsch D. Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review. BMJ Open2014;4(4):e004100. Available from: https://doi.org/10.1136/bmjopen-2013-004100

Cheikh Hassan HI, Tang M, Djurdjev O, Langsford D, Sood MM, Levin A. Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. Kidney Int 2016;90(4):897-904. Available from: https://doi.org/10.1016/j.kint.2016.07.013

Ching C, Schwartz L, Spencer JD, Becknell B. Innate immunity and urinary tract infection. Pediatr Nephrol. 2019 Jun 13. Availa- ble from: https://doi.org/10.1007/s00467-019-04269-9.

Kara E, Sakaci T, Ahbap E, Sahutoglu T, Koc Y, Basturk T, et al. Posttransplant Urinary Tract Infection Rates and Graft Outcome in Kidney Transplantation for End-Stage Renal Disease Due to Reflux Nephropathy Versus Chronic Glomeru- lonephritis. Transplant Proc. 2016 Jul-Aug; 48(6):2065-71.

Ito K, Goto N, Futamura K, Okada M, Yamamoto T, Tsujita M, et al. Death and kidney allograft dysfunction after bacteremia. Clin Exp Nephrol 2016;20(2):309-15. Available from: https://doi.org/10.1007/s10157-015-1155-6

Angelescu K, Nussbaumer-Streit B, Sieben W, Scheibler F, Gartlehner G. Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review. BMC Pregnancy Childbirth 2016;16(1):336. Available from: https://doi.org/10.1186/s12884-016-1128-0

Lee JR, Bang H, Dadhania D, Hartono C, Aull MJ, Satlin M, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation 2013;96(8):732-8. Available from: https://doi.org/10.1097/TP.0b013e3182a04997

Nicolle LE. Urinary tract infection in diabetes. Curr Opin Infect Dis 2005;18(1):49-53. Available from: https://doi.org/10.1097/00001432-200502000-00009

Geerlings SE, Stolk RP, Camps MJ, Netten PM, Hoekstra JB, Bouter KP, et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Dia- betes Care 2000;23(6):744-9. Available from: https://doi.org/10.2337/diacare.23.6.744

Dalet F BE, De Cueto M, Santos M, De la Rosa M. La infección urinaria. Recomendaciones de la Sociedad Española de Enfer- medades Infecciosas y Microbiología Clínica. Procedimientos en Microbiologia Clínica 2003;14.

Andreu Domingo A CJ, Coira Nieto A, Lepe Jiménez JA. Diag- nóstico microbiológico de las infecciones del tracto urinario. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Procedimientos en Mi- crobiología Clínica 2010;14.

Neumann I, Moore P. Pyelonephritis (acute) in non-pregnant women. BMJ Clin Evid 2014;2014.

Gordon I, Barkovics M, Pindoria S, Cole TJ, Woolf AS. Primary vesicoureteric reflux as a predictor of renal damage in children hospitalized with urinary tract infection: a systematic review and meta-analysis. J Am Soc Nephrol 2003;14(3):739-44. Available from: https://doi.org/10.1097/01.asn.0000053416.93518.63

Informe de diálisis y trasplante de 2015. XLVI Congreso Na- cional de la Sociedad Española de Nefrología; Oviedo 2016.

Pigrau C. [Nocosomial urinary tract infections]. Enferm Infecc Microbiol Clin 2013;31(9):614-24. Available from: https://doi.org/10.1016/j.eimc.2012.11.015

Ho HJ, Tan MX, Chen MI, Tan TY, Koo SH, Koong AYL, et al. Interaction between Antibiotic Resistance, Resistance Genes and Treatment Response for Urinary Tract Infections in Primary Care. J Clin Microbiol. 2019 Jun 26. pii: JCM.00143-19. Available from: https://doi.org/10.1128/JCM.00143-19

Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003;17(2):303-32. Available from: https://doi.org/10.1016/s0891-5520(03)00004-7

Roberts JA. Management of pyelonephritis and upper urinary tract infections. Urol Clin North Am 1999;26(4):753-63. Available from: https://doi.org/10.1016/s0094-0143(05)70216-0

Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J, Co- operative Group of the European Study Group on Nosocomial I. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clin Microbiol Infect 2001;7(10):532-42. Available from: https://doi.org/10.1046/j.1198-743x.2001.00324.x

Rishpana MS, Kabbin JS. Candiduria in Catheter Associated Urinary Tract Infection with Special Reference to Biofilm Production. J Clin Diagn Res 2015;9(10):DC11-3. Available from: https://doi.org/10.7860/JCDR/2015/13910.6690

Oteo J, Delgado-Iribarren A, Vega D, Bautista V, Rodriguez MC, Velasco M, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008;32(6):534-7. Available from: https://doi.org/10.1016/j.ijantimicag.2008.06.012

Mena A, Plasencia V, Garcia L, Hidalgo O, Ayestaran JI, Alberti S, et al. Characterization of a large outbreak by CTX-M-1- producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol 2006;44(8):2831-7. Available from: https://doi.org/10.1128/ JCM.00418-06

Rodriguez-Bano J, Pascual A. Clinical significance of exten- ded-spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008;6(5):671-83. Available from: https://doi.org/10.1586/14787210.6.5.671

Lopez-Cerero L, Almirante B. Epidemiology of infections caused by carbapenemase-producing Enterobacteriaceae: reservoirs and transmission mechanisms. Enferm Infecc Microbiol Clin 2014;32 Suppl 4:10-6. Available from: https://doi.org/10.1016/S0213-005X(14)70169-7

De Cueto M, Aliaga L, Alos JI, Canut A, Los-Arcos I, Martinez JA, et al. Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm fecc Microbiol Clin 2016. Available from: https://doi.org/10.1016/j.eimc.2016.11.005

Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004;38(8):1150-8. Available from: https://doi.org/10.1086/383029

Kass EH, Finland M. Asymptomatic infections of the urinary tract. J Urol 2002;168(2):420-4. Available from: https://doi.org/10.1097/00005392-200208000-00004

Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000-2009). BMC Infect Dis 2013;13:19. Available from: https://doi.org/10.1186/1471-2334-13-19

Infectious Lamarche C, Iliuta IA, Kitzler T. Disease Risk in Dialysis Patients: A Transdisciplinary Approach. Can J Kidney Health Dis. 2019 Apr 29;6. Available from: https://doi.org/10.1177/2054358119839080

Chiu PF, Huang CH, Liou HH, Wu CL, Wang SC, Chang CC. Long-term renal outcomes of episodic urinary tract infection in diabetic patients. J Diabetes Complications 2013;27(1):41-3. Available from: https://doi.org/10.1016/j.jdiacomp.2012.08.005

Papapetropoulou M, Papavassiliou J, Legakis NJ. Effect of the pH and osmolality of urine on the antibacterial activity of gentamicin. J Antimicrob Chemother 1983;12(6):571-5. Available from: https://doi.org/10.1093/jac/12.6.571

Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005;293(8):949-55. Available from: https://doi.org/10.1001/jama.293.8.949

Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother. 2013;47(1):106-11. Available from: https://doi.org/10.1345/aph.1R352

Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncompli- cated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000;283(12):1583-90. Available from: https://doi.org/10.1001/jama.283.12.1583

Grabe M B-JT, Botto H, Wullt B, Çek M, Naber KG, et al. UTIs in renal insufficiency, transplant recipients, diabetes mellitus and immunosuppression. Guidelines on urological infections. Guidelines of the European Association of Urology Arnhem, The Netherlands. 2011:45-56. Available from: https://doi.org/10.1086/320900

Snydman DR. Posttransplant microbiological surveillance. Clin Infect Dis 2001;33 Suppl 1:S22-5. Available from: https://doi.org/10.1086/320900

Seroy JT, Grim SA, Reid GE, Wellington T, Clark NM. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. J Antimicrob Chemother 2016;71(9):2563-8. Available from: https://doi.org/10.1093/jac/dkw178

Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta- analysis. Int J Antimicrob Agents 2009;33(2):111-9. Available from: https://doi.org/10.1016/j.ijantimicag.2008.08.011

Benito-Villalvilla C, Cirauqui C, Diez-Rivero CM, Casanovas M, Subiza JL, Palomares O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88.Mucosal Immunol 2017;10(4):924-35. Available from: https://doi.org/10.1038/mi.2016.112

Lorenzo-Gómez MF, Padilla-Fernández B, García-Cenador MB, Virseda-Rodríguez ÁJ, Martín-García I, Sánchez-Escudero A, et al. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections. Front Cell Infect Microbiol 2015;5:50. Available from: https://doi.org/10.3389/fcimb.2015.00050

Lorenzo-Gomez MF, Padilla-Fernandez B, Garcia-Criado FJ, Miron-Canelo JA, Gil-Vicente A, Nieto-Huertos A, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J 2013;24(1):127-34. Available from: https://doi.org/10.1007/s00192-012-1853-5

Yang B, Foley S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. BJU Int 2018; 121(2):289-292. Available from: https://doi.org/10.1111/bju.14067

Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007;177(4):1349-53; quiz 591. Available from: https://doi.org/10.1016/j.juro.2006.11.093

Asadi Karam MR, Habibi M, Bouzari S. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli. Mol Immunol. 2019 Apr; 108:56-67. Available from: https://doi.org/10.1016/j.molimm.2019.02.007

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.


Download data is not yet available.